within Pharmacolibrary.Drugs.ATC.G;

model G03GA07
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 4.066666666666667e-06,
    adminDuration  = 600,
    adminMass      = 75 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0106,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03GA07</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Lutropin alfa is a recombinant human luteinizing hormone (LH) used in combination with follicle stimulating hormone (FSH) for the stimulation of follicular development in women with severe LH and FSH deficiency. It is approved for therapeutic use in assisted reproductive technologies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult women with hypogonadotropic hypogonadism receiving subcutaneous administration.</p><h4>References</h4><ol><li><p>Dhillon, S, &amp; Keating, GM (2008). Lutropin alfa. <i>Drugs</i> 68(11) 1529–1540. DOI:<a href=\"https://doi.org/10.2165/00003495-200868110-00005\">10.2165/00003495-200868110-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18627209/\">https://pubmed.ncbi.nlm.nih.gov/18627209</a></p></li><li><p>Picard, M, Rossier, C, Papasouliotis, O, &amp; Lugan, I (2008). Bioequivalence of recombinant human FSH and recombinant human LH in a fixed 2:1 combination: two phase I, randomised, crossover studies. <i>Current medical research and opinion</i> 24(4) 1199–1208. DOI:<a href=\"https://doi.org/10.1185/030079908x291949\">10.1185/030079908x291949</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18348746/\">https://pubmed.ncbi.nlm.nih.gov/18348746</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03GA07;
